将衰弱与疾病严重程度纳入老年ANCA相关性血管炎治疗决策
诱导方案选择受年龄和衰弱影响:年轻者多用利妥昔单抗联合环磷酰胺,最年长和最衰弱者(包括需住院或养老院照护者)倾向低剂量利妥昔单抗。第一年严重感染再入院率27%,1年死亡率20%;年龄增加与死亡率升高相关(HR 4.15;95%CI:1.62,10.6),与严重感染无关。
要点
- 住院老年重型AAV患者1年死亡率为20%,严重感染再入院率为27%。
- 年龄增加与死亡率升高相关(HR 4.15;95%CI:1.62,10.6),与严重感染无关。
- 依据衰弱与疾病活动度的整体评估调整诱导方案,或可部分抵消年龄相关的感染和死亡风险。
核心结论
- 在住院、重型且高龄的AAV患者中,1年死亡率20%,与较轻且较年轻队列相当,提示按衰弱与疾病活动度整体评估制定诱导策略或可部分减轻年龄增长带来的感染和死亡风险。
研究设计与样本
- 回顾性收集2014至2021年间所有75岁及以上、因重型AAV开始环磷酰胺或利妥昔单抗诱导缓解的住院患者的临床和实验室数据。
主要发现
- 诱导方案分布:利妥昔单抗联合环磷酰胺11.9%、环磷酰胺26.2%、标准剂量利妥昔单抗39.6%、低剂量利妥昔单抗22.3%。
- 第一年严重感染需再入院者占27%,各治疗组分别为37.5%、23.8%、25.8%和31.6%。
- 1年总死亡率为20%,各治疗组分别为10%、23%、14%和26%。
- 年龄增加与死亡率升高相关(HR 4.15;95%CI:1.62,10.6),与严重感染无关(HR 1.18;95%CI:0.47,2.93)。
关键数值与推荐
- 诱导方案选择受年龄和衰弱影响:利妥昔单抗联合环磷酰胺更多用于队列中较年轻患者,低剂量利妥昔单抗更常用于最年长和最衰弱者,包括需住院或养老院照护者。
临床怎么用
- 对住院老年重型AAV患者,诱导缓解方案可结合衰弱与疾病活动度整体评估选择,而不仅依据年龄。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Older patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are underrepresented in clinical trials, and long-term outcome data in this group are limited. We evaluated treatment approaches and outcomes among hospitalized older patients with AAV. METHODS: We retrospectively collected clinical and laboratory data on all hospitalized patients aged 75 years or older who commenced remission induction with cyclophosphamide- or rituximab-based regimens for severe AAV between 2014 and 2021. RESULTS: Eighty-four patients were included (median age 79, range 75-93), with a median follow-up of 21 months (interquartile range 12-44). Choice of induction regimen was influenced by age and frailty: the rituximab-cyclophosphamide combination was more commonly used in younger patients within the cohort, while low-dose rituximab was favoured for the oldest and most frail, including those requiring residential or nursing home care. The distribution of regimens was as follows: rituximab-cyclophosphamide combination (11.9%), cyclophosphamide (26.2%), standard-dose rituximab (39.6%) and low-dose rituximab (22.3%). Serious infection requiring hospital readmission occurred in 27% of patients within the first year, with rates of 37.5%, 23.8%, 25.8% and 31.6% across the respective treatment groups. One-year mortality was 20% overall (by treatment group: 10%, 23%, 14% and 26%). Increasing age was associated with higher mortality (hazard ratio [HR] 4.15; 95% CI: 1.62, 10.6), but not with serious infection (HR 1.18; 95% CI: 0.47, 2.93). CONCLUSION: Considering the enrichment for hospitalized patients with severe disease and advanced age, a mortality rate of 20% at 1 year that is comparable to less severe and younger cohorts suggests tailoring remission induction strategy according to a holistic assessment of frailty and disease activity may partially mitigate the higher risk of infection and mortality with advancing age.
引用
- McClure ME, Sundararajan A, Nelveg-Kristensen KE, et al. Incorporating frailty and disease severity into treatment decisions for older patients with ANCA-associated vasculitis. Rheumatology (Oxford). 2026. PMID: 42185210. doi:10.1093/rheumatology/keag275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。